| 1 |
Dubey AK, Kumar Gupta V, Kujawska M, Orive G, Kim N, Li C, Kumar Mishra Y, Kaushik A. Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases. J Nanostruct Chem. [DOI: 10.1007/s40097-022-00472-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 2 |
Premkumar M, Singh V. Gene Therapy in Liver Disease: Challenges and Outcomes. Biomedical Translational Research 2022. [DOI: 10.1007/978-981-16-8845-4_14] [Reference Citation Analysis]
|
| 3 |
Serajian S, Ahmadpour E, Oliveira SMR, Pereira ML, Heidarzadeh S. CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases. Pharmaceuticals (Basel) 2021;14:1171. [PMID: 34832953 DOI: 10.3390/ph14111171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
González Castro N, Bjelic J, Malhotra G, Huang C, Alsaffar SH. Comparison of the Feasibility, Efficiency, and Safety of Genome Editing Technologies. Int J Mol Sci 2021;22:10355. [PMID: 34638696 DOI: 10.3390/ijms221910355] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Yu M, Liu X, Cheng H, Kuang L, Zhang S, Yan X. Latest progress in the study of nanoparticle-based delivery of the CRISPR/Cas9 system. Methods 2021:S1046-2023(21)00156-0. [PMID: 34107351 DOI: 10.1016/j.ymeth.2021.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Hosseini N, Khanahmad H, Esfahani BN, Bandehpour M, Shariati L, Zahedi N, Kazemi B. Targeting of cholera toxin A (ctxA) gene by zinc finger nuclease: pitfalls of using gene editing tools in prokaryotes. Res Pharm Sci 2020;15:182-90. [PMID: 32582358 DOI: 10.4103/1735-5362.283818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 7 |
Trevisan M, Masi G, Palù G. Genome editing technologies to treat rare liver diseases. Transl Gastroenterol Hepatol 2020;5:23. [PMID: 32258527 DOI: 10.21037/tgh.2019.10.10] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 8 |
Liu Y, Xu Z, Zhang Y, Yu M, Wang S, Gao Y, Liu C, Zhang Y, Gao L, Qi X, Cui H, Pan Q, Li K, Wang X. Marek’s disease virus as a CRISPR/Cas9 delivery system to defend against avian leukosis virus infection in chickens. Veterinary Microbiology 2020;242:108589. [DOI: 10.1016/j.vetmic.2020.108589] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 9 |
Rahbarnia L, Farajnia S, Naghili B, Ahmadzadeh V, Veisi K, Baghban R, Toraby S. Current trends in targeted therapy for drug-resistant infections. Appl Microbiol Biotechnol 2019;103:8301-14. [PMID: 31414162 DOI: 10.1007/s00253-019-10028-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
|
